U.S. Wireless Telecom Stock News

NasdaqGS:CTMX
NasdaqGS:CTMXBiotechs

How Investors Are Reacting To CytomX Therapeutics (CTMX) Equity Raise And Encouraging Varseta-M Trial Data

CytomX Therapeutics recently reported full-year 2025 results showing sales of US$76.2 million and a net loss of US$17.37 million, and has just raised roughly US$250.00 million through a follow-on offering of common stock and pre-funded warrants at about US$5.30 per security. At the same time, the company released encouraging Phase 1 data for its EpCAM-targeted ADC Varseta-M in heavily pretreated metastatic colorectal cancer, with a high disease control rate and a safety profile that appears...
NYSE:TTAM
NYSE:TTAMBasic Materials

Titan America Keystone Deal And 2025 Records Reframe Valuation Story

Titan America (NYSE:TTAM) has agreed to acquire Keystone Cement, expanding its presence and capacity in the Mid-Atlantic region. The company reports record revenue, EBITDA and operating cash flows for 2025, despite sector headwinds. These developments have not yet been widely discussed and may reshape Titan America's growth profile and operational footprint. For investors tracking NYSE:TTAM, the stock last closed at $14.71, with a 1 year return of 15.1% and a 12.0% decline year to date...
NYSE:CALY
NYSE:CALYLeisure

A Look At Callaway Golf’s Valuation After Its Return To The Callaway Name

Callaway Golf stock in focus after name change Callaway Golf (CALY) is back in the spotlight after reverting to its historic name in January 2026, following a period as Topgolf Callaway Brands Corp. The move is drawing fresh attention to its core golf equipment and apparel business. See our latest analysis for Callaway Golf. The recent name change headlines arrive as momentum rebuilds, with a 16.9% year to date share price return and a 107.3% 1 year total shareholder return contrasting with...
NYSEAM:PLX
NYSEAM:PLXBiotechs

A Look At Protalix BioTherapeutics (PLX) Valuation After Elfabrio Dosing Approval And Updated 2026 Revenue Guidance

Why Protalix BioTherapeutics is Back on Investors’ Radar Protalix BioTherapeutics (PLX) has drawn fresh attention after the European Commission approved a new Elfabrio dosing regimen for certain Fabry disease patients, alongside updated 2026 revenue guidance that includes a US$25 million regulatory milestone. See our latest analysis for Protalix BioTherapeutics. The Elfabrio dosing news and 2026 guidance update arrive after a mixed share price pattern, with a 28.9% 90 day share price return...
NYSE:HRB
NYSE:HRBConsumer Services

H&R Block Awards Spotlight AI Tools And Undervalued Share Price

H&R Block (NYSE:HRB) has been named Best Overall Tax Service for 2026. The company also received recognition for Best Use of AI for 2026. These awards highlight H&R Block's AI Tax Assist and Sidekick AI tools in client and professional tax preparation. H&R Block, trading at $30.88, now carries recent recognition as both Best Overall Tax Service and Best Use of AI for 2026, which directly ties to its core tax preparation business. Over 5 years, NYSE:HRB has a return of 77.6%, while the 1...
NasdaqGS:PTEN
NasdaqGS:PTENEnergy Services

Does Patterson UTI Energy (PTEN) Offer Value After Its Strong Recent Share Price Run?

This article examines whether Patterson-UTI Energy is attractively priced or already fully valued by focusing on what the current share price may be implying. The stock last closed at US$10.72, with returns of 8.8% over 7 days, 35.4% over 30 days, 65.7% year to date, 34.6% over 1 year, 12.6% over 3 years and 67.0% over 5 years. These figures may signal shifting views on its prospects and risk. Recent coverage has highlighted Patterson-UTI Energy as an energy services provider. This includes...
NYSE:WT
NYSE:WTCapital Markets

Is It Too Late To Consider WisdomTree (WT) After A 59% One Year Rally?

If you are wondering whether WisdomTree at US$13.86 still offers value after a strong run, a useful starting point is to understand how its current price lines up against different valuation measures. The stock has pulled back 8.5% over the past week and 16.3% over the past month. Even so, it is still up 10.8% year to date and 59.4% over the last year, as well as a very large gain over five years of 153.4%. Recent news flow around WisdomTree has focused on its position within the broader...
NYSE:VNO
NYSE:VNOOffice REITs

Is It Time To Reconsider Vornado Realty Trust (VNO) After Its Recent Share Price Slide?

For investors considering whether Vornado Realty Trust at around US$26.48 reflects enough potential or already embeds too much optimism, this article breaks down what the current share price really represents. The stock has had a mixed run, with a 1.7% gain over the last 7 days, an 8.8% decline over the last 30 days, a 20.8% decline year to date, a 29.9% decline over 1 year, and a 114.6% return over 3 years, compared with a 32.1% decline over 5 years. Recent coverage around Vornado Realty...
NYSE:NATL
NYSE:NATLDiversified Financial

Did Noteholder-Backed Indenture Changes and Earnings Beat Just Shift NCR Atleos' (NATL) Investment Narrative?

On March 11, 2026, NCR Atleos Corporation announced that holders of a majority of its 9.500% Senior Secured Notes due 2029 consented to amendments to the governing indenture, enabling the company, its guarantor subsidiaries, and the trustee to execute a binding supplemental indenture effective immediately. This successful consent solicitation comes shortly after NCR Atleos reported quarterly results with revenue in line with expectations but earnings ahead of forecasts, highlighting the...
NYSE:THO
NYSE:THOAuto

Is THOR Industries (THO) A Potential Opportunity After Recent Share Price Slide?

Wondering whether THOR Industries at around US$76 a share is a bargain or a value trap? This article walks through the numbers so you can judge whether the current price lines up with the fundamentals. The stock has seen a 7.3% decline over the past week, a 33.5% decline over the past month, and is down 27.6% year to date, while the 1-year return sits at a 2.7% decline. These moves have kept THOR Industries on many watchlists, with investors reacting to ongoing headlines around the broader...
NYSE:CBT
NYSE:CBTChemicals

Assessing Cabot (CBT) Valuation After Recent Pullback And Discounted P/E Multiple

Cabot’s recent share performance and business snapshot Cabot (CBT) has seen mixed share performance recently, with a modest 1 day gain, a slight 7 day pullback, and a larger decline over the past month, alongside a positive return over the past 3 months. The specialty chemicals group, headquartered in Boston, reports annual revenue of US$3,607.0 million and net income of US$306.0 million. Its operations span Reinforcement Materials, Performance Chemicals, and smaller unallocated...
NasdaqCM:OVID
NasdaqCM:OVIDBiotechs

A Look At Ovid Therapeutics (OVID) Valuation After OV329 Trial Update And US$60 Million Financing

Ovid Therapeutics (OVID) has drawn fresh attention after reporting Phase 1 data for its OV329 epilepsy program at a 7 mg dose, alongside plans to expand into new seizure indications backed by about US$60 million in private financing. See our latest analysis for Ovid Therapeutics. The new OV329 data and US$60 million financing arrive after a sharp run in the stock, with a 30 day share price return of 60.84% and a 1 year total shareholder return above 400%, even though the 3 year and 5 year...
NasdaqGS:COLL
NasdaqGS:COLLPharmaceuticals

Collegium Pharmaceutical Expands ADHD Portfolio With AZSTARYS And Valuation Gap

Collegium Pharmaceutical (NasdaqGS:COLL) has entered into a definitive agreement to acquire AZSTARYS. The deal expands Collegium’s ADHD portfolio and secures longer-term product exclusivity for its ADHD offerings. The transaction is described as immediately accretive to adjusted EBITDA. For investors following the ADHD treatment space, this move provides another data point on how branded therapies are being repositioned. Collegium, which focuses on pain and ADHD treatments, is adding...
NYSE:ACM
NYSE:ACMConstruction

Is It Time To Reassess AECOM (ACM) After Recent Share Price Pullback?

If you are wondering whether AECOM’s current share price really reflects what you are getting for your money, this article breaks down the key numbers so you can judge the value for yourself. The stock most recently closed at US$90.32, with returns of 0.6% over 7 days, a 1.0% decline over 30 days, a 6.3% decline year to date, and a 3.9% decline over the last year. Over a longer horizon, AECOM has delivered total returns of 15.0% over 3 years and 49.3% over 5 years, which gives important...
NasdaqGS:NBTB
NasdaqGS:NBTBBanks

Is It Time To Reassess NBT Bancorp (NBTB) After Recent Share Price Weakness?

If you are wondering whether NBT Bancorp at around US$40.97 is starting to look interesting, the current share price and fundamentals raise some clear valuation questions worth unpacking. The stock has seen a 0.7% decline over the last week, a 10.4% decline over the past month, and a 1.5% decline year to date, while the 1 year, 3 year, and 5 year returns stand at a 1.9% decline, 34.7%, and 21.3% respectively. Recent attention on regional banks, regulatory capital expectations, and investor...
NasdaqGS:MGNI
NasdaqGS:MGNIMedia

Magnite’s NOVA Retail Audio Deal Might Change The Case For Investing In Magnite (MGNI)

In March 2026, Magnite announced a partnership with NOVA Entertainment to power programmatic buying across the Nova Retail Network, giving advertisers automated access to premium in-store digital audio inventory that reaches millions of Australian shoppers at the point of purchase. This collaboration highlights how Magnite is extending its sell-side technology and AI-driven workflow tools into high-impact retail audio environments, aligning with growing programmatic adoption across audio...
NasdaqGM:FLY
NasdaqGM:FLYAerospace & Defense

Firefly Aerospace’s Record 2025 Reshapes Moon, Defense And Valuation Story

Firefly Aerospace (NasdaqGM:FLY) completed its first commercial moon landing in 2025, expanding its activity beyond Earth orbit missions. The company listed its shares in a high profile IPO in 2025, providing wider access to capital markets. Firefly reported major revenue growth in 2025 and acquired SciTec to deepen its national security and defense related offerings. For investors tracking Firefly Aerospace at a current share price of $22.96, 2025 marked a shift in scale and scope. The...
NYSE:GLOB
NYSE:GLOBIT

Globant Taps AI Cancer Research And Payments Deals As Shares Lag Targets

Globant (NYSE:GLOB) announced an AI focused collaboration with PharmaMar to support cancer drug discovery efforts. The company also agreed a global integration partnership with payments platform Adyen for enterprise clients. Both arrangements position Globant in healthcare and fintech projects tied to drug research and digital payments infrastructure. Globant operates as a digital services and technology company, working with enterprises that are investing in cloud, data and AI based...
NasdaqGM:LUNR
NasdaqGM:LUNRAerospace & Defense

Intuitive Machines (LUNR) Q4 Loss Of US$19.9 Million Tests Profitability Narrative

Intuitive Machines (LUNR) closed FY 2025 with Q4 revenue of US$44.8 million and a basic EPS loss of US$0.17, alongside a net loss of US$19.9 million, while on a trailing 12 month basis revenue was US$210.1 million and EPS stood at a loss of US$0.71 with a net loss of US$83.9 million. Over recent quarters, the company has seen quarterly revenue move from US$62.5 million in Q1 2025 to US$50.3 million in Q2, US$52.4 million in Q3 and US$44.8 million in Q4, with EPS losses ranging between US$0.06...
NYSE:NSC
NYSE:NSCTransportation

Is Norfolk Southern (NSC) Pricing Look Stretched After Recent Share Price Pullback?

If you are wondering whether Norfolk Southern's current share price truly reflects its fundamentals, this breakdown is designed to help you frame that valuation question clearly. The stock closed at US$278.19, with returns of 4.5% decline over 7 days, 12.0% decline over 30 days, 3.3% decline year to date, but 21.5% over 1 year, 49.3% over 3 years and 15.2% over 5 years, which gives mixed signals about how the market has been reassessing the company. Recent market attention has focused on...
NYSE:DRI
NYSE:DRIHospitality

Is It Time To Revisit Darden Restaurants (DRI) After The Recent Share Price Pullback

If you are wondering whether Darden Restaurants at around US$204 per share still offers value, the key is to look past the headline price and focus on what the underlying business might be worth. The stock has returned 3.0% over the last 7 days, while the 30 day return sits at a 6.5% decline, with returns of 9.2% year to date, 5.8% over 1 year, 49.8% over 3 years and 65.9% over 5 years. Recent coverage has focused on Darden Restaurants as a large US casual dining group with a portfolio of...
NYSE:SNOW
NYSE:SNOWIT

Snowflake’s Project SnowWork Shifts AI Narrative Toward Action And Adoption

Snowflake (NYSE:SNOW) has introduced Project SnowWork, an autonomous enterprise AI platform for business users. The platform is designed to execute complex multi step workflows from conversational prompts while maintaining data governance and security. Project SnowWork extends Snowflake's role from analytics to AI driven action and workflow automation across enterprise data. Snowflake enters this launch with its shares at $175.4 and a mixed return profile, including a 19.1% decline year to...
NYSE:UAMY
NYSE:UAMYMetals and Mining

United States Antimony Contracts Recast Critical Minerals And Tungsten Growth Story

United States Antimony (NYSE:UAMY) secured a U.S. government contract worth more than $248m for antimony ingots in the past week. The company reported an additional $354m in new antimony agreements, expanding its role in critical mineral supply chains. UAMY announced an acquisition of a tungsten asset in Ontario, targeting domestic tungsten production for North America. The company restarted antimony mining in Montana and is increasing processing capacity with active government...
NasdaqCM:FMNB
NasdaqCM:FMNBBanks

Is Farmers National Banc (FMNB) Share Price Misjudging Its Excess Returns And Premium P/E Ratio

Wondering if Farmers National Banc at around US$12.66 is a bargain or fairly priced? This article breaks down what that share price might actually reflect about the company’s underlying value. The stock has returned 2.3% over the last 7 days, alongside a 5.9% decline over 30 days and a 4.6% decline year to date. Over 3 years the return sits at 17.7%, while the 1 year and 5 year returns are around 0.0% and a 1.0% decline respectively. Recent news coverage has focused on Farmers National...